Akorn lays out $45M for Sunovion lung drug; Sanofi teams with Indian hospitals on diabetes clinics;

> Sunovion Pharmaceuticals said it would sell off rights to its respiratory drug Xoponex (levalbuterol) to Akorn ($AKRX) for $45 million. Release

> Sanofi ($SNY) teamed up with India's Apollo Hospitals on a diabetes-care program in India, delivered through a network of Apollo Sugar Clinics. Report

> Merck Serono tapped Hutchison China MediTech to market its beta blocker Ziac (bisoprolol HCl) in China. Report

> Pfizer Canada and WestJet launched a social media contest to raise awareness of anaphylaxis; Pfizer ($PFE) markets EpiPen in that country. Release

And Finally... Novo Nordisk ($NVO) and Diabetes UK started an awareness campaign, "Talk Hypos," to encourage diabetes patients to report hypoglycemia to their doctor or nurse. Release

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.